[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
|
[2]
|
王少明, 郑荣寿, 张思维, 曾红梅, 陈茹, 孙可欣, 等. 2015年中国胃癌流行特征分析[J]. 中华流行病学杂志, 2019, 40(12): 1517-1521.
|
[3]
|
Sasako, M., Sakuramoto, S., Katai, H., Kinoshita, T., Furukawa, H., Yamaguchi, T., et al. (2011) Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy with S-1 versus Surgery alone in Stage II or III Gastric Cancer. Journal of Clinical Oncology, 29, 4387-4393. https://doi.org/10.1200/JCO.2011.36.5908
|
[4]
|
Petrillo, A., Pompella, L., Tirino, G., Pappalardo, A., Laterza, M.M., Caterino, M., et al. (2019) Perioperative Treatment Inresectable Gastric Cancer: Current Perspectives and Future Directions. Cancers, 11, Article No. 399.
https://doi.org/10.3390/cancers11030399
|
[5]
|
Smith, D.D., Schwarz, R.R. and Schwarz, R.E. (2005) Impact of Total Lymph Nodecount on Staging and Survival After Gastrectomy for Gastric Cancer: Data from a Large US-Population Database. Journal of Clinical Oncology, 23, 7114-7124. https://doi.org/10.1200/JCO.2005.14.621
|
[6]
|
王玮, 孙哲, 邓靖宇, 王振宁, 周志伟, 梁寒, 等. 基于多中心大样本数据库的胃癌外科治疗相关数据的整合与分析[J]. 中华胃肠外科杂志, 2016, 19(2): 179-185.
|
[7]
|
Bang, Y.J., Kim, Y.W., Yang, H.K., Chung, H.C., Park, Y.-K., Lee, K.H., et al. (2012) Adjuvant Capecitabine and Oxaliplatin for Gastric Cancer after D2 Gastrectomy (CLASSIC): A Phase 3 Open-Label, Randomised Controlled trial. Lancet, 379, 315-321. https://doi.org/10.1016/S0140-6736(11)61873-4
|
[8]
|
Das, M. (2017) Neoadjuvant Chemotherapy: Survival Benefit in Gastric Cancer. The Lancet Oncology, 18, e307.
https://doi.org/10.1016/S1470-2045(17)30321-2
|
[9]
|
Hu, Y., Hu, D., Li, W, et al. (2019) Neoadjuvant Chemotherapy Brings More Survival Benefits Than Postoperative Chemotherapy for Resectable Gastric Cancer: A Meta-Analysis of Randomized Controlled Trials. Journal of BUON, 24, 201-214.
|
[10]
|
Heinemann, V. and Moosmann, N. (2007) Neoadjuvant and Adjuvant Therapies for Solid Tumours. MMW Fortschritte der Medizin, 149, 27-30.
|
[11]
|
Cunningham, D., Allum, W.H., Stenning, S.P., Thompson, J.N., Van de Velde, C.J.H., Nicolson, M., et al. (2006) Perioperative Chemotherapy versus Surgery alone for Resectable Gastroesophageal Cancer. New England Journal of Medicine, 355, 11-20. https://doi.org/10.1056/NEJMoa055531
|
[12]
|
Ychou, M., Boige, V., Pignon, J., Conroy, T., Bouché, O., Lebreton, G., et al. (2011) Perioperative Chemotherapy Compared with Surgery alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. Journal of Clinical Oncology, 29, 1715-1721. https://doi.org/10.1200/JCO.2010.33.0597
|
[13]
|
Zhang, X.T., Liang, H., Li, Z.Y., Xue, Y.W., Wang, Y., Zhou, Z.W., et al. (2021) Perioperative or Postoperative Adjuvant Oxaliplatin with S-1 versus Adjuvant Oxaliplatin with Capecitabine in Patients with Locally Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma Undergoing D2 Gastrectomy (RESOLVE): An Open-Label, Superiority and Non-Inferiority, Phase 3 Randomised Controlled Trial. Lancet Oncology, 22, 1081-1092.
https://doi.org/10.1016/S1470-2045(21)00297-7
|
[14]
|
Endo, S., Imano, M., Furukawa, H., Yokokawa, M., Nishimura, Y., Shinkai, M., et al. (2019) Phase II Study of Preoperative Radiotherapy Combined with S-1 Plus Cisplatin in Clinically Resectable Type 4 or Large Type 3 Gastric Cancer: OGSG1205. Annals of Oncology, 30, v302. https://doi.org/10.1093/annonc/mdz247.110
|
[15]
|
Al-Batran, S.E., Homann, N., Pauligk, C., Goetze, T.O., Meiler, J., Kasper, S., et al. (2019) Perioperative Chemotherapy with Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel versus Fluorouracil or Capecitabine Plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial. Lancet Oncology, 393, 1948-1957. https://doi.org/10.1016/S0140-6736(18)32557-1
|
[16]
|
Terazawa, T., Matsuyama, J., Goto, M., Kawabata, R., Endo, S., Imano, M., et al. (2020) A Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601). Oncologist, 25, 119-e208. https://doi.org/10.1634/theoncologist.2019-0601
|
[17]
|
Wang, X.X., Li, S., Xie, T.Y., Lu, Y., Guo, X. and Lin, C. (2020) Early Results of the Randomized, Multicenter, Controlled Evaluation of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Chinese Advanced Gastric Cancer Patients(RESONANCE Trial). Journal of Clinical Oncology, 38, S280. https://doi.org/10.1200/JCO.2020.38.4_suppl.280
|
[18]
|
Yu, Y.Y., Fang, Y., Shen, Z.B., Wang, Y., Yan, M., Cao, H., et al. (2019) Oxaliplatin Plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC Study. Oncologist, 24, 1311-e989. https://doi.org/10.1634/theoncologist.2019-0416
|
[19]
|
Al-Batran, S.E., Hofheinz, R.D., Pauligk, C., Kopp, H.-G., Haag, G.M., Luley, K.B., et al. (2016) Histopathological Regression after Neoadjuvant Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin versus Epirubicin, Cisplatin, and Fluorouracil or Capecitabine in Patients with Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4-AIO): Results from the Phase 2 Part of a Multicentre, Open-Label, Randomised Phase 2/3 Trial. Lancet Oncology, 17, 1697-1708. https://doi.org/10.1016/S1470-2045(16)30531-9
|